COG
NEUTRALCambridge Cognition Holdings Plc Announces Holding(s) in Company
The healthcare technology company has announced changes to its major shareholders.
Cambridge Cognition Holdings
36.00GBX
-2.70%
Market Cap
15.07M
Volume
46
0% of avg
P/E Ratio
0.14
EPS (TTM)
2.63
Beta
Day Range
36.00p - 36.00p
52 Week Range
26.40p36.00p48.00p
36.00p
Upcoming Events
COG
BADCambridge Cognition Reports Revenue Decline but Improved EBITDA Loss in 2024
The brain health software group reported a 23.7% revenue decline but reduced its EBITDA loss. Despite cost-cutting measures and recent order book growth, financial challenges and market headwinds persist.
COG
NEUTRALCambridge Cognition Announces Preliminary Results Presentation
The healthcare technology company will announce its preliminary results and host an investor presentation next month.
COG
VERY GOODCambridge Cognition Secures £1 Million Contract for Autoimmune Disease Trial
The healthcare technology company has secured a £1 million contract for a major Phase 3 autoimmune disease clinical trial, representing a significant opportunity to expand its presence in the high-impact CNS trials market.
COG
NEUTRALCambridge Cognition Announces Holding Change
The healthcare technology company has announced a change in shareholding, with an investor increasing their stake to over 10% of the company.
COG
GOODCambridge Cognition Wins £1.2 Million in Contracts for Phase 3 MDD Trials
The healthcare technology company has secured two major contracts worth £1.2 million to provide digital cognitive and voice assessments for Phase 3 clinical trials in adolescent depression.
COG
GOODCambridge Cognition's CANTAB platform selected for major brain health study
The neuroscience technology company's cognitive assessment platform was chosen for a large-scale brain health study, validating its capabilities and representing a significant market opportunity.
COG
NEUTRALCambridge Cognition Submits FDA Letter of Intent for Cognitive Impairment Assessments
The neuroscience technology company has submitted a Letter of Intent to the FDA to develop an objective measure of cognitive impairment in schizophrenia, aiming to streamline clinical trials and accelerate treatment development.
COG
NEUTRALCambridge Cognition Appoints New Non-Executive Director
The healthcare technology company has appointed a new independent non-executive director with extensive public company experience and financial expertise.
COG
GOODCambridge Cognition Expands Services with Launch of In-House Rater Training
The healthcare technology company is launching a new in-house rater training service, expanding its portfolio of digital products for the central nervous system market.